VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. Part of Cytiva’s BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received… Read More
VANCOUVER, B.C. — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the closing of its previously announced underwritten public offering of 11,035,000 common shares, including the… Read More
VANCOUVER, B.C. — Acuitas Therapeutics is excited to announce that it has entered into a sponsorship agreement with the 2022 Greater Vancouver Regional Science Fair (GVRSF). This is a partner-level… Read More
Recommendation based on pivotal trial that showed Dupixent significantly reduced severe asthma attacks and improved lung function in children aged 6 to 11 Dupixent is the only biologic to show… Read More
Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with… Read More
